

Molecular Foundations of Cancer: A Narrative Review of Hallmarks, Microenvironment, and Precision Therapeutic Advances

Sathyananth M, Jenifer C, T. Leon Stephan Raj

Department of Botany, St. Xavier's College (Autonomous), Palayamkottai - 627002, Tamilnadu, India.

Abstract

Background: Cancer represents a devastating global health challenge characterized by intricate molecular mechanisms that defy conventional therapeutic approaches. This review integrates contemporary scientific understanding of the biological processes underlying cancer, exploring the complex interplay among genetic, cellular, and microenvironmental factors that drive tumor development. It critically examines pivotal hallmarks such as dysregulated cellular proliferation, metastatic potential, and immune system interactions. Central molecular signaling pathways, including MAPK and PI3K-AKT, are analyzed to reveal the dynamics of malignant transformation. Furthermore, the exploration of the tumor microenvironment and cellular metabolic adaptations illustrates the resilience of cancer cells. The aim of this narrative review is to synthesize foundational molecular mechanisms and emerging precision therapeutic strategies to provide a comprehensive perspective on the molecular complexity of cancer. **Conclusion:** Emerging therapeutic strategies represent a paradigm shift towards precision medicine, leveraging targeted molecular interventions, immunotherapy, and advanced nanotechnology. This review provides a unique synthesis by specifically linking foundational mechanisms, such as epigenetic modifications, to the pathological heterogeneity observed in tumors. By integrating current scientific knowledge and technological innovations like CAR-T therapies, this work provides a comprehensive perspective on the future of personalized cancer management.

Keywords: Cancer Molecular Mechanisms- Tumor Microenvironment- Precision Medicine- Cellular Signalling

Asian Pac J Cancer Care, **11** (2), 265-280

Submission Date: 10/12/2025 Acceptance Date: 01/04/2026

1. Introduction

Cancer is a multifaceted disease that causes over 10 million deaths annually, worldwide. It is characterised by diverse biological traits and a wide range of phenotypes [1, 2]. Breast cancer, the most prevalent malignant tumor among women, exemplifies this heterogeneity through its varied cellular states and interactions [3]. This complexity arises from the interplay of genetic, environmental, and host factors, resulting in biological heterogeneity that influences the pathophysiology, tumor biology, and clinical outcomes [4]. Research indicates that bulk tumors often originate from “cancer stem cells” (CSCs), which are responsible for cancer initiation and recurrence [1]. Epigenetic mechanisms are integral to cancer development, alter cellular states, and play a significant role in tumour origin and progression [1].

The global impact and complexity of cancer necessitate ongoing molecular research to enhance clinical care and develop personalised treatments. Advanced technologies, such as single-cell RNA sequencing (scRNA-seq), are revolutionising cancer research by providing insights into cellular heterogeneity [3]. Understanding molecular characteristics at the genomic level is crucial for improving clinical care and developing personalised precision medicine approaches for patients with cancer [4]. The aim of this narrative review is to synthesize the foundational molecular mechanisms, the complexities of the tumor microenvironment, and emerging precision therapeutic strategies to provide a comprehensive perspective on the current landscape of oncology.

Corresponding Author:

Dr. T. Leon Stephan Raj

Assistant Professor, Director – PMRU, Department of Botany, St. Xavier's College (Autonomous), Palayamkottai - 627002, Tamilnadu, India.

Email: leostephanraj@gmail.com.

2. Cellular Foundations of Cancer

Normal cell cycle and regulation

The eukaryotic cell cycle involves the synthesis and degradation of cyclins that activate cyclin-dependent kinases (CDKs) [5]. Key proteins, including cyclins, CDKs, and the inhibitors p21 and p16, control cell proliferation at checkpoints [5]. These checkpoints function as DNA surveillance mechanisms during cell division [6]. In response to damage, checkpoints can delay progression or induce cell cycle exit or apoptosis [6]. CDC25 phosphatases are crucial in cell cycle phase transitions and are targets of the checkpoint machinery [7]. Meiotic cycles have checkpoints that ensure recombination completion before spindle formation and proper chromosomal attachment. Animal oocytes maintain meiotic arrest via cyostatic factors [8]. Cell cycle regulation occurs through temporal and spatial information, including the synthesis and activation of proteins that regulate gene expression. Checkpoints link cell division to chromosome states, whereas regulatory components direct organelle positioning [9]. Understanding these mechanisms is crucial for developing cancer therapies and addressing cell cycle disorders.

Fundamental cellular alterations in cancer

Cancer development involves cellular modifications, including genetic disruption and molecular changes, that enable malignant progression. Genetic inactivation of tumor suppressor genes such as p16 (INK4a)/p14 (ARF) and NF2 and epigenetic silencing of genes such as RASSF1A are prevalent in cancers. The activation of receptor tyrosine kinases and deregulation of the MAPK and PI3K-AKT signalling pathways contribute to cancer cell survival [10]. Although specific oncogene mutations, such as KRAS, are common in certain cancers, they are not universal [10, 11]. Cancer is characterised by dysregulation of pathways that drive aberrant cell growth. Cellular transformation involves oncogene activation and tumour suppressor inactivation [11]. The

interaction between genetic mutations, epigenetic changes, and altered signalling contributes to cancer progression. Understanding these processes is vital for developing targeted therapies and improving treatment.

Hallmarks of cancer development

Cancer progression is characterized by uncontrolled growth and systemic transformation. The framework of Hanahan and Weinberg (2000,) [12] explains the complexity and adaptability of cancer [13, 14]. Core hallmarks include sustained proliferative signalling, evasion of growth suppressors, resistance to cell death, replicative immortality, angiogenesis, and metastasis [13, 15, 16]. Emerging hallmarks include dysregulated cellular energetics, immune evasion, genome instability, and tumor-promoting inflammation [14]. The AKT pathway influences multiple hallmarks, thereby affecting cellular physiology and oncogenesis [14]. TGF- β functions as a tumor suppressor in normal cells and promotes tumor growth in malignant cells [16]. Understanding these hallmarks is crucial for developing targeted therapies. The multifaceted nature of cancer requires comprehensive approaches addressing tumor biology [17, 18] (Table 1).

3. Genetic and Molecular Basis of Cancer

Genomic instability

Genomic instability, a defining characteristic of cancer, arises from chromosomal aberrations, failures of the DNA damage response (DDR), and structural alterations. DNA damage can result from endogenous sources, such as replication errors, or exogenous factors, such as radiation and chemicals, leading to nucleotide changes or chromosomal abnormalities [19]. Unrepaired damage disrupts cellular homeostasis, activates oncogenes, inactivates tumor suppressors, and drives carcinogenesis [19, 20]. Chromosomal instability encompasses karyotypic changes, copy-number alterations, and structural abnormalities [20]. DNA-damaging events, such as chromothripsis and chromoplexy, can cause extensive

Table 1. Key Cancer Hallmarks and Corresponding Targeted Therapeutic Strategies

| Hallmark | Key Molecular Mechanism(s) | Example Therapeutic Class / Drug |
|-------------------------------------|--|---|
| Sustained Proliferative Signalling | Oncogene activation (e.g., EGFR, HER2, BRAF) | Tyrosine Kinase Inhibitors (e.g., Osimertinib, Trastuzumab, Dabrafenib) |
| Evasion of Growth Suppressors | Inactivation of RB pathway | CDK4/6 Inhibitors (e.g., Palbociclib) |
| Resistance to Cell Death | Overexpression of anti-apoptotic proteins (e.g., BCL-2) | BH3 Mimetics (e.g., Venetoclax) |
| Replicative Immortality | Telomerase activation | Telomerase Inhibitors (e.g., Imetelstat) |
| Induction of Angiogenesis | Upregulation of VEGF | Anti-VEGF Monoclonal Antibodies (e.g., Bevacizumab) |
| Activation of Invasion & Metastasis | EMT activation; HGF/c-MET signalling | MET Inhibitors (e.g., Crizotinib) |
| Deregulating Cellular Energetics | Warburg effect; IDH mutations | IDH Inhibitors (e.g., Ivosidenib); Glycolysis inhibitors (experimental) |
| Genome Instability & Mutation | Defective DNA Damage Response (DDR) (e.g., BRCA mutations) | PARP Inhibitors (e.g., Olaparib) |
| Avoiding Immune Destruction | Expression of immune checkpoints (e.g., PD-L1) | Immune Checkpoint Inhibitors (e.g., Pembrolizumab, Nivolumab) |
| Tumor-Promoting Inflammation | Inflammatory signalling (e.g., NF- κ B) | Anti-inflammatory drugs (e.g., IL-6 inhibitors, JAK inhibitors) |

genomic insults and exacerbate genomic instability in cancers [21]. Defects in the DDR pathway can lead to aberrant DNA repair and tumorigenesis [22]. Dysfunctional telomeres trigger DDR activation, causing chromosome-end fusion and genomic instability [22]. Abnormalities in DDR-associated genes and dysfunctional ubiquitin-proteasome systems are prevalent in metastatic castration-resistant prostate cancer [23]. Understanding these mechanisms is crucial for developing novel prognostic biomarkers and targeted therapies [21, 23]. Clinically, instability can be assessed by using histopathological tools. Immunohistochemistry (IHC) for mismatch repair (MMR) proteins is a standard method for screening Lynch syndrome and has become a critical pan-tumor biomarker for immune checkpoint inhibitor responses [24]. Loss of nuclear staining for these proteins provides a visual correlation to genomic defects and has therapeutic implications [25].

Oncogenes and tumor suppressor genes

Oncogene activation and tumor suppressor gene silencing are pivotal for cancer initiation and progression. Oncogenes, which are proto-oncogenes involved in cell growth, can be activated by gene amplification, chromosomal rearrangements, or mutations [26, 27]. This activation led to uncontrolled cell proliferation. Tumor suppressor genes that inhibit cell transformation and regulate cell cycle control and apoptosis are inactivated in cancer cells through mutations, deletions, or epigenetic silencing [28, 29]. Studies have shown a correlation between oncogene activation and epigenetic silencing of specific tumor suppressor genes [30]. The transcriptional repressor Id1, which is overexpressed in numerous cancers, targets tumor suppressor genes such as TSP1 and CDKN2A (p16). The precise mechanism of this silencing remains unclear, as Id1 overexpression alone does not repress these target genes in melanoma cell lines [30] (Healey et al., 2010). This suggests that oncogene activation may require additional genetic or epigenetic alterations to silence the tumor suppressor genes. The interplay between oncogene activation and silencing of tumor suppressor genes is complex. Understanding these mechanisms is crucial to developing novel cancer therapies. Emerging techniques, such as RNA interference, zinc finger nucleases, and CRISPR, offer promising avenues for targeting these molecular pathways in cancer treatment [26].

Genetic mutations and cancer progression

Driver mutations confer a selective advantage to cancer cells, while passenger mutations are considered neutral or mildly harmful [31]. Drivers are the primary contributors to carcinogenesis, while passengers have minimal impact. Recent studies have shown complex interactions among these mutations during cancer evolution. Computational models suggest that passenger mutations can accelerate cancer evolution by reducing population fitness and boosting the fitness of intermediate mutants in tumor suppressor gene inactivation pathways [32, 33]. This suggests that the

baseline rate of tumor suppressor gene inactivation may be faster than previously thought. Although some passenger mutations harm cancer cells, their cumulative effect creates a barrier to cancer progression, defined by critical population-size and mutation-rate thresholds [34]. The genetic evolution of cancer involves balancing the driver and passenger mutations. Although drivers mainly propel cancer progression, passenger accumulation can significantly affect tumor fitness and treatment outcomes. This understanding has implications for cancer therapy, suggesting that targeting the collective burden of passenger mutations is promising [34, 35]. The timing and dependencies of mutations, including low-frequency drivers, are crucial in cancer genomics [36].

Epigenetic modifications

Epigenetic modifications include DNA methylation, histone modifications, chromatin remodeling, gene regulation, and cancer development. DNA methylation, particularly promoter hypermethylation, can silence tumor suppressor genes and contribute to cancer progression [37]. Histone modifications affect chromatin structure and gene expression, with aberrant patterns found in various tumor types [38, 39]. Interactions between epigenetic mechanisms increase the complexity of gene regulation in cancer. Crosstalk between N6-methyladenosine (m6A) RNA methylation and other epigenetic modifications initiates epigenetic remodeling and influences tumorigenesis [40]. The relationship between histone modifications and regulatory elements in breast cancer cells shows that active regulatory elements are associated with active histone modifications near transcription start sites [41]. Dysregulation of epigenetic mechanisms contributes to cancer development. The reversible nature of these modifications has led to epigenetic therapies targeting the enzymes involved in DNA methylation and histone modifications [37, 38]. Understanding the interplay between epigenetic mechanisms and their roles in gene regulation is crucial for developing effective cancer treatments and advancing the knowledge of tumor biology [42].

Genomic landscape of cancer

Genomic analyses of different cancer types have revealed a landscape of genetic alterations, including mutations, copy number changes, and structural variations. Whole-genome sequencing of 403 adult gliomas has identified recurrent coding and non-coding mutations, providing a map of structural variants and copy-number changes [43]. Analysis of 33,036 solid tumors showed that copy number changes in cancer driver genes are broadly prognostic, whereas mutations are rarely associated with patient survival [44]. There are discrepancies in the prognostic value of genetic alterations. Although mutations in cancer driver genes do not correlate with patient outcomes, copy number changes and methylation patterns are more informative for risk assessment [44]. The genetic landscape varies among the cancer types. RHOA mutations were observed in 14.3% of diffuse-type gastric tumors but not in intestinal-type tumors [45]. The

genomic terrain of cancer shows heterogeneity across cancer types. Mutations, copy-number alterations, and structural variations contribute to molecular signatures. Integrating genomic, epigenomic, and transcriptomic profiles provides an understanding of cancer biology and may improve diagnostic, prognostic, and therapeutic strategies [45, 46]. This approach offers insight into personalized medicine and targeted therapies. In clinical practice, Next-Generation Sequencing (NGS) panels are used to analyze tumor genomics. The data, identifying driver mutations, copy number alterations, and fusions, are discussed by molecular tumor boards (MTBs) to recommend targeted therapies or determine prognosis. Integrating genomic data into clinical decision-making is essential for precision oncology [47].

4. Molecular Signalling in Cancer Development

Cell proliferation signalling pathways

Protein kinases play a pivotal role in cellular signalling, governing cell growth, proliferation, and survival [48]. These networks encompassing numerous kinases and phosphorylation sites are frequently dysregulated in cancer. MAPK cascades convey signals to intracellular targets and initiate cell proliferation, differentiation, and apoptosis [49]. In cancer, mutations or aberrant protein expression can disrupt these networks uncontrolled cellular growth. Ras G-proteins, which regulate MAPK pathways, are mutated in approximately 30% of human cancers [50], highlighting the need for targeted therapies. Research shows more kinases than previously recognized contribute to tumorigenesis, suggesting new therapeutic strategies [48]. The complexity of these networks is demonstrated by pathway interactions; cAMP can modulate growth factor responses by decoupling MAPK cascades and activating signals via PKA [51]. Understanding these interactions and molecular alterations in signalling pathways is essential for elucidating cancer growth circuits and developing effective therapies.

Apoptosis and cell survival mechanisms

Cancer cells employ molecular strategies to circumvent cell death, a fundamental characteristic of malignancy, by suppressing apoptosis and resistance to pro-death signals [52]. Dysregulated apoptosis contributes to cancer progression and resistance to treatments such as radiation and cytotoxic drugs [53]. Cancer cell survival depends on the overexpression of anti-apoptotic proteins, such as Bcl-2, which confer resistance to apoptosis-inducing agents and are activated in lymphomas and other cancers [53]. Resistance develops through mutations in pro-apoptotic genes, increased expression of anti-apoptotic proteins, and the silencing of pro-apoptotic genes via DNA hypermethylation [54]. Studies have shown that endocytosis plays a key role in apoptotic resistance and immune escape, with tumors exhibiting dysregulated endocytic dynamics that support metabolic demands and resistance to therapy [55]. Alternative cell death pathways, such as ferroptosis, entosis, necroptosis, and immunogenic cell death, present new intervention

opportunities [56]. Cancer cells resist death by disrupting apoptotic pathways and altering endocytic dynamics. Understanding these mechanisms is crucial for developing therapies targeting the apoptotic machinery and alternative cell death mechanisms for effective cancer treatment [55-57].

Growth factor signalling

Receptor tyrosine kinases (RTKs) are integral to cellular communication through growth factor signalling. These transmembrane proteins are activated upon ligand binding, inducing receptor dimerization and autophosphorylation of tyrosine residues within the intracellular domains [58]. This activation triggers signal transduction cascades involving adaptor proteins and enzymes that regulate cellular processes, including growth, differentiation, metabolism, and motility [59]. RTKs can also translocate to the nucleus to initiate transcription [60]. Proteomic studies have identified novel post-translational modification sites, highlighting the complexity of these networks [61]. Aberrant RTK signalling occurs during cancer progression through receptor overexpression, mutations, gene amplification, and defective regulation [60, 62]. These changes activate pathways, such as MAPK, PI3K/Akt, and JAK/STAT, promoting cancer stemness, angiogenesis, and metastasis [62]. Although RTKs are attractive therapeutic targets, resistance and toxicity challenge RTK-targeted therapies [63], underscoring the need for new approaches to modulate these pathways in cancer treatment.

Cellular communication and transformation

Cancer cells interact through molecular transformations and signalling networks to establish tumor progression and immune evasion [64]. These interactions occur via extracellular vesicle (EVs)-transferring of proteins, nucleic acids, and microRNAs between cells [65]. The tumor microenvironment (TME) enables intercellular communication, in which tumor-associated macrophages (TAMs) maintain immunosuppression through EVs [66]. Adipocytes in the breast stroma secrete EVs that promote tumor growth [65]. Tunneling nanotubes (TNTs) enable direct intercellular transport, which affects cellular reprogramming and chemotherapy resistance [67]. Cancer cells use these pathways to modify their TME. Understanding these interactions is vital to developing novel therapeutic strategies. Single-cell RNA sequencing and tools such as CellChat have enhanced our understanding, potentially leading to improved anticancer therapies [68-71].

Immune system evasion mechanisms

Cancer cells utilize molecular mechanisms to evade immune surveillance and resist immune checkpoint inhibitors (ICIs). These mechanisms include the modulation of immune checkpoints, molecular alterations, and systemic immune resistance. Cancer cells evade immune attacks by modulating immune checkpoints, with tumors upregulating inhibitory checkpoints, such as PD-1/PD-L1 and CTLA-4, to suppress T cell activity [72, 73].

Alternative immune checkpoint activation contributes to resistance to PD-1/PD-L1 inhibitors [74]. The triggering receptor TREM2 negatively affects antitumor immunity by inhibiting T cell proliferation [75]. Cancer cells evade detection through neoantigen loss or impaired antigen presentation [74]. Epithelial-mesenchymal transition facilitates immune evasion by altering the expression of checkpoint molecules [76]. Epigenetic modifications alter the expression of immune response genes and contribute to drug resistance [74]. Cancer cells create an immunosuppressive tumor microenvironment by reprogramming their metabolism to generate nutrient scarcity and hypoxia [77] (Jiang et al., 2020). “Cold” tumors lacking T cell infiltration render ICI therapy ineffective [78], while gut microbiome dysbiosis contributes to resistance [74]. Understanding these mechanisms is crucial to developing strategies to overcome resistance. Solutions include combining ICIs with alternative checkpoint therapies and enhancing T cell infiltration [72, 78].

5. Cancer Microenvironment

Tumor microenvironment composition

The cellular landscape of cancer is defined by interactions between cancer cells and tumor microenvironment (TME) components, forming a dynamic ecosystem that supports cancer cell survival and growth [79, 80]. Cancer cells interact with stromal, endothelial, and immune cells, creating an ecosystem that facilitates tumor progression and treatment resistance [80]. TME comprises immune cells, stromal cells, and soluble factors that interact with cancer cells [79]. This crosstalk shapes the immune landscape and influences tumor progression and therapeutic response [79, 81]. Cancer-associated fibroblasts (CAFs) undergo phenotypic changes that affect tumor growth, promote cancer cell survival, and facilitate immune evasion [82]. The extracellular matrix (ECM) regulates cell growth, survival, and migration through cellular interactions [83]. Cancer cell plasticity enables environmental adaptation, contributing to tumor diversity and drug resistance through processes such as epithelial-mesenchymal transition [84]. Metabolic interplay within the TME supports cancer cell proliferation [82]. Understanding the interactions and mechanisms underlying tumor heterogeneity and drug resistance is crucial for developing effective cancer therapies [79, 81, 84].

Role of stromal cells

The tumor microenvironment (TME) is integral to cancer progression and metastasis through interactions between cancer cells, stromal cells, and extracellular matrix (ECM) components. These interactions form communication networks that support tumor growth and invasion [85-87]. Cancer-associated fibroblasts (CAFs) are crucial within the TME for synthesizing and modulating the ECM, which serves as a scaffold for growth factors and cytokines that promote tumor growth and metastasis [88]. ECM components regulate growth factors, such as

hepatocyte growth factor (HGF) and its receptor c-MET, influencing cellular processes, including proliferation and angiogenesis [86]. Gap junctions (GJs) show context-dependent effects on cancer progression, potentially inhibiting metastasis in some models, while promoting epithelial-to-mesenchymal transition (EMT) in breast cancer [89]. Stromal dynamics of cancer progression involve complex communication networks and molecular pathways. Understanding these interactions is crucial for developing TME-targeted therapies and for improving cancer management [90, 91].

Inflammation and cancer progression

Inflammation plays a dual role in cancer, functioning as both a protective mechanism and a potential catalyst for tumorigenesis. Acute inflammation defends against pathogens and tissue damage, whereas chronic inflammation can facilitate malignant transformation [92]. The inflammatory microenvironment is regulated by mediators, including cytokines (TNF- α , IL-6, TGF- β , and IL-10), chemokines, and growth factors, which contribute to tumor progression [93]. A bidirectional relationship exists between inflammation and cancer; chronic inflammation can lead to cancer, and cancer cells can induce inflammatory responses that support tumor development. Breast cancer cells produce TSLP, triggering dendritic cells to express OX40L, which in turn drives the development of inflammatory Th2 cells that promote tumor growth [94]. The IL-6 amplifying mechanism, involving NF- κ B and STAT3, sustains chronic inflammation and drives tumorigenesis [95]. Molecular triggers such as PAMPs and DAMPs initiate chronic inflammatory responses [96], creating conditions for tumor development by inducing DNA damage, promoting cell proliferation, and suppressing antitumor immunity. Understanding these interactions is essential for developing targeted therapies against inflammation-associated malignancies.

Angiogenesis

Blood vessel formation involves multiple molecular switches that are critical for tumor nutrient acquisition and growth, including vasculogenesis and angiogenesis [97, 98]. Hypoxia and the hypoxia-inducible factor (HIF) transcriptional system trigger blood vessel growth in malignant tumors [99]. HIF-1 α stabilization under hypoxic conditions increases the transcription of proangiogenic genes, particularly vascular endothelial growth factor (VEGF) [98]. The angiogenic switch involves transitioning from a pre-vascular to a vascularized tumor phenotype, which is controlled by pro- and anti-angiogenic factors [100]. Vascular remodeling integrates existing vessels into tumor vasculature and vessel regression, transforming healthy networks into tumor-specific vasculature [101]. This process is influenced by molecular pathways, cell activities, microenvironment, and mechanical forces [101]. NRP1 is essential for embryonic angiogenesis and vessel remodeling [102]. Understanding these mechanisms is crucial for developing therapeutic strategies that target tumor angiogenesis. Computer simulations can provide

insights into blood flow and drug distribution, thereby facilitating effective treatment protocols [101, 103].

Extracellular matrix interactions

Invasion of cancer cells involves interactions between tumor cells and the extracellular matrix (ECM) via various molecular mechanisms. This process involves cytoskeletal dynamics, cell-ECM adhesion, and tissue remodeling in response to microenvironmental signals [104]. Tumor cells use collective and single-cell migration strategies to adapt to microenvironmental challenges [104]. During tumor progression, the ECM undergoes remodeling, with cancer cells and stromal fibroblasts producing matrices and enzymes that support invasion [105]. The tensional force field from cell contraction drives collagen fiber remodeling, which enhances cell polarization and invasion by increasing the matrix stiffness [106]. Cellular contractility is essential because its inhibition reduces tumor cell invasion. The interaction between cellular mechanics and ECM remodeling reveals mechanochemical coupling during invasion [106]. Key molecules involved in invasion include integrins, focal adhesion kinase (FAK), and matrix metalloproteases (MMPs). Integrins mediate cell-ECM adhesion, whereas FAK mediates integrin signalling [107, 108]. MMPs facilitate ECM degradation, and MMP-2 plays a significant role [109]. Cancer-associated fibroblasts contribute to ECM remodeling, promoting tumor rigidity, and FAK activation [110]. Cancer cell invasion involves cellular and molecular mechanisms that enable tumor cells to adapt to microenvironmental conditions and therapeutic challenges.

6. Metastasis Mechanisms

Invasion and migration processes

Cancer cell migration and invasion are complex processes involving multiple mechanisms that enable tumor cells to escape from primary sites and metastasize [104,111]. These processes exhibit plasticity and adaptability, allowing cancer cells to respond to microenvironmental cues and overcome therapies [104, 112]. The primary mechanisms include collective, mesenchymal, and amoeboid cell migration, distinguished by cell-cell junctions, actin cytoskeleton organization, matrix adhesion, and protease activity [112]. Cancer cells can transition between these migration modes, demonstrating plasticity that helps them navigate microenvironments and evade therapies [112, 113]. Migration and invasion involve interplay between cellular components and signalling pathways, including cytoskeletal remodeling, ECM degradation, and cell adhesion changes [108, 111]. Cross-talk between the ECM, integrin receptors, matrix metalloproteases, and Rho GTPases modulates cell shape, tension, and migration [108]. The tumor microenvironment influences collective tumor cell invasion [114]. This plasticity manifests itself as histopathological changes. During Epithelial-Mesenchymal Transition (EMT), epithelial cells lose polarity and cell-cell adhesion while gaining mesenchymal




Figure 1. Histopathologic and Molecular View of EMT

markers, thereby driving invasion [115]. This process is visible at tumor ‘invasive fronts.’ Tumor grading reflects this process, with high-grade tumors showing loss of epithelial architecture and a discohesive appearance consistent with EMT, indicating an invasive potential [116] (Figure 1).

Metastatic cascade

Metastatic progression of cancer involves molecular events and cellular transformations that enable tumor cells to spread from primary sites to distant organs. The metastatic cascade begins when cancer cells acquire pro-metastatic characteristics and develop a supportive tumor microenvironment (TME) [117]. This process involves loss of cell polarity, altered adhesion, and deregulated receptor kinase signalling, enabling tumor cell detachment and invasion. Epithelial-to-mesenchymal transition (EMT) is critical, marked by decreased E-cadherin and increased vimentin and Twist1/2 expression (Sridaran et al., 2016). Cancer cells must overcome anoikis and immune surveillance before leaving the primary tumor [117]. The tumor stroma engages in molecular crosstalk within the TME, promoting angiogenesis and immunosuppressive responses. Circulating tumor cells face challenges during their intravasal journey [117]. CTCs interact with the immune system and may be more susceptible to immune effector cells [118]. Successfully extravasating CTCs can colonize distant sites and adapt to survival [117, 119]. This process involves interactions between tumor cells and their microenvironment, creating an immunosuppressive milieu that fosters metastatic tumors [119].

Molecular determinants of metastasis

Metastasis, the leading cause of cancer mortality, involves complex events regulated by molecular factors and signalling pathways. Reactive oxygen species (ROS) signalling facilitates the metastatic cascade and SIRT3 regulates cell migration through ROS control [120]. The invasion-metastasis cascade is influenced by pathways

including TGF β , Wnt/ β -Catenin, Hedgehog, p53, and cancer stem cell maintenance, which are modulated by proteins like Kindlin-2 [121]. NF- κ B is critical in pancreatic cancer metastasis, regulating cell proliferation, anti-apoptosis, angiogenesis, epithelial-mesenchymal transition, and inflammation [122]. The MAP pathway, regulated by RKIP, contributes to cell growth, invasion, and metastasis [123]. Hypoxia-induced alterations mediated by HIF-1 and pathways, such as c-Src and c-Met, contribute to the metastatic phenotype [124]. It defines that metastasis is regulated by molecular factors and pathways, including ROS signalling, NF- κ B, MAP, and hypoxia-induced pathways. Understanding these mechanisms is essential for developing targeted therapies to prevent metastasis. The involvement of tumour stromal cells, particularly endothelial cells, in early tumour metastasis underscores the complexity of this process [125].

Organ-specific metastasis

Cancer cells demonstrate organ-specific preferences during metastasis through interactions between the tumour cells and the target organ microenvironment. Organ tropism is influenced by several mechanisms. The metastatic cascade selectively favours the survival of specific subpopulations of metastatic cells within the primary tumour [126]. These cells have properties that enable organ colonisation. Breast cancer cells exhibit organ-specific malignant behaviour in response to organ-conditioned media, matching their *in vivo* metastatic potential [127]. The organ microenvironment is crucial for metastatic colonisation. As proposed by Paget's "seed and soil" hypothesis, the organ microenvironment influences tumour cell invasion, survival, growth, and apoptosis [126]. This interaction occurs via paracrine stimulation by organ-derived growth factors and cytokines [126, 128]. A key insight into this hypothesis is the pre-metastatic niche (PMN), where primary tumours "prepare" distant sites by secreting extracellular vesicles (EVs) that create a favourable microenvironment [129]. Organ-specific metastasis results from the interplay between cancer cell properties and organ microenvironment characteristics. Understanding these mechanisms is crucial for developing targeted therapies and predicting metastasis. Future research should focus on organ-derived factors influencing metastatic and the pre-metastatic niche role [127, 129].

Metastatic colonization

Cancer cells employ mechanisms to colonise distant organs and form secondary tumours. Metastasis involves escape from primary tumours, survival in circulation, and organ colonisation. Cancer stem cells are crucial for initiating new tumours at secondary sites [130]. To colonise organs, cancer cells must overcome shear stress and adapt to new microenvironments [131]. Cancer cells reprogram their metabolism to survive in new environments. This metabolic reprogramming of amino acid metabolism is essential for colonisation of organs such as the lung, liver, brain, peritoneum, and bone [132]. Primary tumours secrete extracellular vesicles (EVs) to form pre-metastatic niches (PMN) that prepare distant

sites for colonisation [133]. Metastatic colonisation depends on interactions between cancer cells and the host microenvironment, involving metabolic adaptations and niche formation. Understanding these mechanisms is crucial for developing therapies to prevent metastasis, the main cause of cancer mortality [131-133].

7. Cellular Metabolism in Cancer

Metabolic reprogramming

Cancer cells undergo metabolic reprogramming to facilitate rapid growth and survival in adverse conditions. This metabolic adaptability allows them to fulfil their energy needs and sustain their viability in challenging environments [134]. Key alterations include the Warburg effect and changes in lactate, glutamine, and lipid metabolism to supply intermediates for nucleotide, protein, and fatty acid biosynthesis [135, 136]. Recent research indicates that cancer cells depend on glutamine, lipids, and mitochondrial metabolism [137]. The carnitine system regulates metabolic flexibility, enabling transition between glucose and fatty acid metabolism [134]. MicroRNAs (miRNAs) modulate these metabolic changes and often act as downregulated tumour suppressors in cancer [135, 137]. Cancer cells utilise metabolic reprogramming strategies involving glycolysis, glutaminolysis, lipid metabolism, and mitochondrial function [138, 139]. Understanding these adaptations offers opportunities to develop innovative diagnostic tools and therapeutic strategies [137, 140]. A notable example is the 'porphyrin overdrive' mechanism, an imbalanced heme-metabolic pathway representing a promising target for future therapies [141].

Warburg effect

The Warburg effect is a metabolic phenomenon in cancer cells characterised by increased glycolysis and lactate production even in the presence of adequate oxygen [142]. This metabolic reprogramming enables cancer cells to fulfil energy and biosynthetic requirements for rapid proliferation [143].

The Warburg effect includes key metabolic alterations:

1. A preference for aerobic glycolysis over oxidative phosphorylation for ATP production [143].
2. An increase in glucose uptake and lactate production [144].
3. Reprogramming of mitochondrial oxidative phosphorylation [145].
4. Activation of lactate dehydrogenase A to convert pyruvate into lactate [144].

While the Warburg effect is a hallmark of cancer metabolism, its universality remains debated. Some studies show that certain cancer cells exhibit high mitochondrial respiration and low glycolysis [146]. The 'reverse Warburg effect' proposes that glycolytic stromal cells secrete lactate, which is used by oxidative cancer cells, highlighting complex metabolic interactions within the TME [146].

The Warburg effect provides advantages to cancer cells:

Table 2. Key Metabolic Vulnerabilities in Cancer and Potential Therapeutic Targets

| Metabolic Pathway | Key Alterations in Cancer | Rationale for Targeting | Example Therapeutic Strategy |
|-------------------------------------|---|---|---|
| Glucose Metabolism (Warburg Effect) | Increased aerobic glycolysis | High glucose uptake and lactate production | Glycolysis inhibitors (e.g., 2-DG) MCT1 inhibitors (block lactate export) |
| Glutamine Metabolism | "Glutamine addiction" for biosynthesis | Cancer cells depend on glutamine for nitrogen and anaplerosis | Glutaminase (GLS) inhibitors (e.g., CB-839) |
| Lipid Metabolism | De novo fatty acid synthesis | Required for building new cell membranes | Fatty Acid Synthase (FASN) inhibitors |
| One-Carbon Metabolism | High demand for folate pathway | Needed for nucleotide (purine/pyrimidine) synthesis | Antifolates (e.g., Methotrexate) |
| Amino Acid Metabolism | Dependency on specific amino acids (e.g., Arginine, Serine) | Some tumors cannot synthesize these "non-essential" amino acids | Arginine-degrading enzymes (Arginase) |

1. Rapid energy production and increased proliferation [143].

2. Enhanced survival under hypoxic conditions [144].

3. Support for tumor progression and resistance to cell death (Coelho et al., 2018).

4. Promotion of invasiveness and metastasis [144].

These metabolic alterations confer growth advantages to cancer cells and contribute to therapy resistance. Understanding this reprogramming offers opportunities for targeted cancer therapies [142, 144].

Metabolic vulnerabilities

Cancer cells possess metabolic vulnerabilities that can be targeted because of their altered metabolic processes (Table 2). These vulnerabilities arise from metabolic reprogramming during tumor development [147, 148]. A key vulnerability is modified glucose metabolism. Tumors rely on glycolysis for energy production, even in the presence of oxygen (the Warburg effect), which can be exploited with glycolysis inhibitors [149, 150]. The increased lactate production has led to therapies targeting lactate transporters (MCTs) [151]. Another vulnerability is glutamine metabolism dependence, vital for biosynthesis and energy. Glutaminase inhibitors show potential here [149, 150, 152]. Some tumours rely on mitochondrial oxidative phosphorylation (OXPHOS), making them susceptible to OXPHOS inhibitors [149, 151]. Other vulnerabilities include lipid and nucleotide metabolism, as well as specific pathways [147, 153]. Targeting metabolic interactions between cancer cells and tumour microenvironment shows promise [154, 155]. Cancer cells' metabolic reprogramming offers exploitable vulnerabilities through inhibitors and combination therapies. However, tumour heterogeneity and adaptive resistance require personalised approaches and predictive biomarkers [149, 150].

Metabolic interactions in tumor microenvironment

Metabolic interactions between cancer cells and the tumor microenvironment (TME) are crucial for cancer progression. Cancer cells undergo metabolic reprogramming, altering their glucose and lipid metabolism to adapt to the TME [156, 157]. This reprogramming affects surrounding cells, creating metabolic crosstalk within the TME [66, 158]. Cancer cells stimulate adipocytes to release fatty acids, thereby supporting their growth

and survival [159]. These interactions are reciprocal. Cancer-associated fibroblasts (CAFs) and stromal cells influence cancer cell metabolism by supplying nutrients and signals that promote tumor growth and metastasis [160]. Metabolic changes in immune cells within the TME alter their function, potentially enabling cancer cells to evade the immune response [159, 160]. Metabolic interactions between cancer cells and the TME create a supportive environment for tumor growth, metastasis, and therapy resistance. Understanding these interactions offers opportunities to develop therapies targeting metabolic pathways in cancer cells and the TME [156, 157, 160].

8. Molecular Therapeutic Approaches

Targeted therapies

Targeted therapies represent a cutting-edge approach to cancer treatment, designed to address molecular and genetic abnormalities that drive tumor growth [161]. These therapies disrupt specific receptor signaling pathways that are crucial for tumor cell proliferation, survival, and migration [162]. Targeted therapies include small-molecule inhibitors, monoclonal antibodies, antibody-drug conjugates, and gene-editing technologies [161]. Their success depends on precise detection and sustained targeting of initial and evolving driver mutations within cancer cells [163]. In non-small cell lung cancer (NSCLC), targeted therapies address specific molecular alterations, such as EGFR mutations, ALK and ROS1 fusions, and BRAF, RET, MET, HER2, and KRAS alterations [164]. This enables personalized treatment, tailoring therapies to a patient's tumor's molecular profile [165]. However, challenges persist, including tumor heterogeneity and clonal evolution, leading to drug resistance and treatment failure [163]. While some targeted therapies have shown significant efficacy, others have produced suboptimal outcomes in clinical trials [166]. The development of targeted therapies, driven by advances in molecular profiling techniques, represents progress towards more effective and personalized cancer care [161, 164].

Immunotherapy mechanisms

Precision medicine customizes cancer treatments for individual patients by considering their genetic, molecular, and clinical characteristics to deliver more effective

therapies while reducing adverse effects. In oncology, precision medicine applies genetic and patient-specific information to optimize preventive and therapeutic care [167]. It uses biomarkers, including genetic, epigenetic, protein, and metabolite markers, to identify patients who are candidates for targeted therapies [168]. This approach has enabled companion diagnostics, where molecular assays measure proteins, genes, or mutations to provide tailored therapy [167]. Patient-derived tumor organoids, combined with genomic sequencing and drug screening, allow researchers to model personalized therapeutic responses [169]. Circulating biomarkers assess patient risk and tumor characteristics and monitor treatment outcomes [170]. Precision medicine aims to complement standard approaches by tailoring treatments to unique tumor characteristics [171]. By integrating genomic profiling and targeted therapies, precision medicine offers the potential to improve cancer treatment outcomes [161, 172]. However, challenges including tumor heterogeneity, limited biomarkers, high costs, and resistance to targeted therapies must be addressed [168] (Figure 2).

Precision medicine

Precision medicine customizes cancer treatments for individual patients by considering their genetic, molecular, and clinical characteristics to deliver more effective therapies while reducing adverse effects. In oncology, precision medicine applies genetic and patient-specific information to optimize preventive and therapeutic care [167]. It uses biomarkers, including genetic, epigenetic, protein, and metabolite markers, to identify patients who are suited for targeted therapies [168]. This approach has enabled companion diagnostics, where molecular assays measure proteins, genes, or mutations to provide tailored therapy [167]. Patient-derived tumor organoids, combined with genomic sequencing and drug screening, enable researchers to model personalized therapeutic responses [169]. Circulating biomarkers assess patient risk and tumor characteristics and monitor treatment outcomes [170]. Precision medicine aims to complement standard approaches by tailoring treatments to unique tumor characteristics [171]. By integrating genomic profiling and targeted therapies, precision medicine offers the potential to improve cancer treatment outcomes [161, 172]. However, challenges including tumor heterogeneity, limited biomarkers, high costs, and resistance to targeted therapies must be addressed [168].

Emerging therapeutic strategies

The latest emerging therapeutic strategies for cancer treatment encompass innovative approaches to overcome drug resistance and enhance patient outcomes. Targeted therapies, combination treatments, and immunotherapies have demonstrated significant potential in addressing cancer's molecular mechanisms [173]. Nanotechnology-enhanced photodynamic therapy (PDT) with immunotherapy has shown synergistic effects in preclinical studies, enhancing immune responses and mitigating the immunosuppressive tumor microenvironment [174]. Smart therapeutic carriers

have emerged as an effective strategy to improve drug delivery and patient outcomes, with promise for cancer immunotherapy. Two-dimensional molybdenum disulfide (MoS₂) has demonstrated potential as a platform for cancer theranostics, offering applications in imaging, photothermal therapy, and drug delivery [175]. Emerging therapies for pancreatic cancer include immunotherapy, genetic profiling, and targeted approaches [176]. Targeted therapies and personalized strategies are being investigated to address CRC treatment resistance [177]. Precision medicine and immunotherapy are transforming lung cancer treatment [178]. Cancer therapeutics is rapidly evolving, emphasizing personalized approaches that leverage nanotechnology, immunotherapy, and molecular biology for improved outcomes.

Molecular targeting approaches

Molecular targeting strategies enhance the specificity and efficacy of cancer therapy by focusing on tumor cells' unique molecular characteristics. These methodologies identify and target specific molecules involved in cancer growth, enabling personalized treatments. Targeted therapies deliver anticancer agents to tumor cells while minimizing damage to adjacent cells, resulting in higher effective doses and improved responses [179]. Aptamers, single-stranded oligonucleotides, bind to target molecules with high specificity, promoting localization and uptake by specific cell populations [179]. Advancements in genomics, proteomics, and transcriptomics have identified molecular targets, leading to the development of monoclonal antibodies and intracellular targeting agents [180]. These therapies inhibit cancer cell proliferation by interfering with tumor growth molecules [181]. Small-molecule inhibitors and antibody-drug conjugates enhance treatment precision [161]. Molecular-targeting approaches enable precise, personalized treatments based on tumors' genetic and molecular characteristics. This shift




Figure 2. Clinical Workflow of Precision Oncology

from organ-centric to personalized approaches has enabled more effective cancer treatments (Silva et al., 2023; Silva et al., 2024). However, drug resistance, toxicity, and high costs remain challenges to these therapies [181].

In conclusion, cancer is an intricate and evolving disease system shaped by the interplay of genetic mutations, cellular dynamics, and microenvironmental influences. A comprehensive understanding of these molecular mechanisms is essential for developing effective therapeutic strategies. Precision medicine, supported by advances in genomics and molecular profiling, continues to redefine treatment paradigms through targeted and personalized interventions. The integration of artificial intelligence and machine learning into cancer research is accelerating the discovery of predictive biomarkers and therapeutic targets, while patient-derived models such as tumor organoids are enhancing the precision of drug screening and individualized therapy design. Collectively, these emerging approaches signal a transition toward more adaptive, data-driven oncology one that aims not merely to treat but to manage cancer as a chronic, controllable condition.

Declarations

Clinical trial registration

Not applicable.

Conflicts of interest/Competing interests

The authors declare that they have no competing interests.

Availability of data and material

Not applicable. As this is a review article, all data synthesized are from previously published studies, which are fully cited in the reference list.

Code availability

Not applicable.

Authors' contributions

S.M. contributed to the conception, design, and final drafting of the manuscript. S.M. and J.C. contributed to the literature search and primary drafting of the manuscript. T.L.S.R. supervised the study. All authors read and approved the final manuscript for submission.

Ethics approval

Not applicable. This article is a review of existing literature and does not involve any new studies on human or animal subjects.

Consent to participate

Not applicable.

Consent for publication

Not applicable.

Acknowledgments

The authors wish to acknowledge the management and faculty of St. Xavier's College (Autonomous), Palayamkottai, for providing the institutional support and academic environment that facilitated this research.

Originality Declaration for Figures

All figures included in this manuscript are original and have been created by the authors specifically for the purposes of this study. No previously published or copyrighted images have been used. The authors confirm that all graphical elements, illustrations, and visual materials were generated from the data obtained in the course of this research or designed uniquely for this manuscript.

Declaration on generative AI and AI-assisted technologies in the writing process

During the preparation of this manuscript, the authors used AI-assisted technologies (Grammarly and Turnitin) for grammar checking, plagiarism detection, and initial outlining.

References

1. Das KJ, Stella JH, Saunders M, et al. Epigenetic modulation of cancer stem cells in vitro 3D models. *Cancer Stem Cells and Signaling Pathways*. 2024 01 01;:381-394. <https://doi.org/10.1016/B978-0-443-13212-4.00035-0>
2. Zgura A, Gales L, Bratila E, Mehedintu C, Haineala B, Barac RI, Popa AR, et al. Variation of the T Lymphocytes According to Treatment in Breast Cancer. *Revista de Chimie*. 2019 06 15;70(5):1649-1654.
3. Xiang L, Rao J, Yuan J, Xie T, Yan H. Single-Cell RNA-Sequencing: Opening New Horizons for Breast Cancer Research. *International Journal of Molecular Sciences*. 2024 08 31;25(17):9482. <https://doi.org/10.3390/ijms25179482>
4. Choi YY, Noh SH, Cheong J. Molecular Dimensions of Gastric Cancer: Translational and Clinical Perspectives. *Journal of Pathology and Translational Medicine*. 2016 01;50(1):1-9. <https://doi.org/10.4132/jptm.2015.09.10>
5. Johnson MJ, Walker ID, Sproule MW, Conkie J. Abnormal coagulation and deep venous thrombosis in patients with advanced cancer. *Clinical and Laboratory Haematology*. 1999 02;21(1):51-54. <https://doi.org/10.1046/j.1365-2257.1999.00163.x>
6. Matthews HK, Bertoli C, Bruin RAM. Cell cycle control in cancer. *Nature Reviews. Molecular Cell Biology*. 2022 01;23(1):74-88. <https://doi.org/10.1038/s41580-021-00404-3>
7. Sadeghi F, Asgari M, Matloubi M, Ranjbar M, Karkhaneh Yousefi N, Azari T, Zaki-Dizaji M. Molecular contribution of BRCA1 and BRCA2 to genome instability in breast cancer patients: review of radiosensitivity assays. *Biological Procedures Online*. 2020;22:23. <https://doi.org/10.1186/s12575-020-00133-5>
8. Russo AA, Tong L, Lee JO, Jeffrey PD, Pavletich NP. Structural basis for inhibition of the cyclin-dependent kinase Cdk6 by the tumour suppressor p16INK4a. *Nature*. 1998 09 17;395(6699):237-243. <https://doi.org/10.1038/26155>
9. Jenal U, Stephens C. The Caulobacter cell cycle: timing, spatial organization and checkpoints. *Current Opinion in Microbiology*. 2002 Dec;5(6):558-563. [https://doi.org/10.1016/S1471-0158\(02\)00033-5](https://doi.org/10.1016/S1471-0158(02)00033-5)

- org/10.1016/s1369-5274(02)00378-8
10. Sekido Y. Genomic abnormalities and signal transduction dysregulation in malignant mesothelioma cells. *Cancer Science*. 2010 01;101(1):1-6. <https://doi.org/10.1111/j.1349-7006.2009.01336.x>
 11. Cheng NC, Vonderheide RH. Immune vulnerabilities of mutant KRAS in pancreatic cancer. *Trends in Cancer*. 2023 Nov;9(11):928-936. <https://doi.org/10.1016/j.trecan.2023.07.004>
 12. Hanahan D, Weinberg RA. The Hallmarks of Cancer. *Cell*. 2000 01 07;100(1):57-70. [https://doi.org/10.1016/S0092-8674\(00\)81683-9](https://doi.org/10.1016/S0092-8674(00)81683-9)
 13. Gimla M, Herman-Antosiewicz A. Multifaceted Properties of Usnic Acid in Disrupting Cancer Hallmarks. *Biomedicines*. 2024 09 26;12(10):2199. <https://doi.org/10.3390/biomedicines12102199>
 14. Sementino E, Hassan D, Bellacosa A, Testa JR. AKT and the Hallmarks of Cancer. *Cancer Research*. 2024 Dec 16;84(24):4126-4139. <https://doi.org/10.1158/0008-5472.CAN-24-1846>
 15. Gong H, Nie D, Li Z. Targeting Six Hallmarks of Cancer in Ovarian Cancer Therapy. *Current Cancer Drug Targets*. 2020;20(11):853-867. <https://doi.org/10.2174/1568009620999200816130218>
 16. Tian M, Neil JR, Schiemann WP. Transforming growth factor- β and the hallmarks of cancer. *Cellular Signalling*. 2011 06;23(6):951-962. <https://doi.org/10.1016/j.cellsig.2010.10.015>
 17. Limami Y, Pinon A, Wahnou H, Oudghiri M, Liagre B, Simon A, Duval RE. Ursolic Acid's Alluring Journey: One Triterpenoid vs. Cancer Hallmarks. *Molecules*. 2023 Dec 01;28(23):7897. <https://doi.org/10.3390/molecules28237897>
 18. Zuo W, Pang Q, Zhu X, Yang Q, Zhao Q, He G, Han B, Huang W. Heat shock proteins as hallmarks of cancer: insights from molecular mechanisms to therapeutic strategies. *Journal of Hematology & Oncology*. 2024 09 04;17(1):81. <https://doi.org/10.1186/s13045-024-01601-1>
 19. Salmaninejad A, Ilkhani K, Marzban H, Navashenaq JG, Rahimirad S, Radnia F, Yousefi M, et al. Genomic Instability in Cancer: Molecular Mechanisms and Therapeutic Potentials. *Current Pharmaceutical Design*. 2021;27(28):3161-3169. <https://doi.org/10.2174/1381612827666210426100206>
 20. Chan SH, Ngeow J. Germline mutation contribution to chromosomal instability. *Endocrine-Related Cancer*. 2017 09;24(9):T33-T46. <https://doi.org/10.1530/ERC-17-0062>
 21. Tapia-Laliena MA, Korzeniewski N, Hohenfellner M, Duensing S. High-risk prostate cancer: a disease of genomic instability. *Urologic Oncology*. 2014 Nov;32(8):1101-1107. <https://doi.org/10.1016/j.urolonc.2014.02.005>
 22. Lazzarini-Denchi E, Sfeir A. Stop pulling my strings - what telomeres taught us about the DNA damage response. *Nature Reviews. Molecular Cell Biology*. 2016 06;17(6):364-378. <https://doi.org/10.1038/nrm.2016.43>
 23. Lin Y, Jin X. Effect of ubiquitin protease system on DNA damage response in prostate cancer (Review). *Experimental and Therapeutic Medicine*. 2024 01;27(1):33. <https://doi.org/10.3892/etm.2023.12321>
 24. Luchini C, Bibeau F, Ligtenberg MJL, Singh N, Nottegar A, Bosse T, Miller R, et al. ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1/PD-L1 expression and tumour mutational burden: a systematic review-based approach. *Annals of Oncology: Official Journal of the European Society for Medical Oncology*. 2019 08 01;30(8):1232-1243. <https://doi.org/10.1093/annonc/mdz116>
 25. Le DT, Durham JN, Smith KN, Wang H, Bartlett BR, Aulakh LK, Lu S, et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. *Science*. 2017 07 28;357(6349):409-413. <https://doi.org/10.1126/science.aan6733>
 26. Goshu B. *Molecular Biology for Cancer Therapy: Review Articles*. 2021 06 10;. <https://doi.org/10.20944/preprints202106.0290.v1>
 27. Matson RS. *Oligonucleotide Arrays for the Detection of ras Mutations*. Springer Berlin Heidelberg. 2000;:724-37. https://doi.org/10.1007/978-3-642-57206-7_64
 28. Hollingsworth RE, Lee WH. Tumor suppressor genes: new prospects for cancer research. *Journal of the National Cancer Institute*. 1991 01 16;83(2):91-96. <https://doi.org/10.1093/jnci/83.2.91>
 29. Oliveira AM, Ross JS, Fletcher JA. Tumor suppressor genes in breast cancer: the gatekeepers and the caretakers. *American Journal of Clinical Pathology*. 2005 Dec;124 Suppl:S16-28. <https://doi.org/10.1309/5XW3L8LU445QWGQR>
 30. Healey MA, Deaton SL, Alder JK, Winnepenninckx V, Casero RA, Herman JG. Id1 overexpression is independent of repression and epigenetic silencing of tumor suppressor genes in melanoma. *Epigenetics*. 2010 07 01;5(5):410-421. <https://doi.org/10.4161/epi.5.5.11929>
 31. Zhang J, Liu J, Sun J, Chen C, Foltz G, Lin B. Identifying driver mutations from sequencing data of heterogeneous tumors in the era of personalized genome sequencing. *Briefings in Bioinformatics*. 2014 03;15(2):244-255. <https://doi.org/10.1093/bib/bbt042>
 32. Wodarz D, Komarova NL, Newell AC. Passenger mutations can accelerate tumor suppressor gene inactivation in cancer evolution [Preprint]. *Cold Spring Harbor Laboratory*; 2017. <https://doi.org/10.1101/202531>
 33. Wodarz D, Newell AC, Komarova NL. Passenger mutations can accelerate tumour suppressor gene inactivation in cancer evolution. *Journal of the Royal Society, Interface*. 2018 06;15(143):20170967. <https://doi.org/10.1098/rsif.2017.0967>
 34. McFarland CD, Mirny LA, Korolev KS. Tug-of-war between driver and passenger mutations in cancer and other adaptive processes. *Proceedings of the National Academy of Sciences of the United States of America*. 2014 Oct 21;111(42):15138-15143. <https://doi.org/10.1073/pnas.1404341111>
 35. McFarland CD, Yaglom JA, Wojtkowiak JW, Scott JG, Morse DL, Sherman MY, Mirny LA. The Damaging Effect of Passenger Mutations on Cancer Progression. *Cancer Research*. 2017 09 15;77(18):4763-4772. <https://doi.org/10.1158/0008-5472.CAN-15-3283-T>
 36. Sakoparnig T, Fried P, Beerenwinkel N. Identification of constrained cancer driver genes based on mutation timing. *PLoS computational biology*. 2015 01;11(1):e1004027. <https://doi.org/10.1371/journal.pcbi.1004027>
 37. Baylin SB. DNA methylation and gene silencing in cancer. *Nature Clinical Practice. Oncology*. 2005 Dec;2 Suppl 1:S4-11. <https://doi.org/10.1038/ncponc0354>
 38. Ellis L, Atadja PW, Johnstone RW. Epigenetics in cancer: targeting chromatin modifications. *Molecular Cancer Therapeutics*. 2009 06;8(6):1409-1420. <https://doi.org/10.1158/1535-7163.MCT-08-0860>
 39. Ramazi S, Dadzadi M, Sahafnejad Z, et al. Histone modification and personalized epigenomics in cancer. *Personalized Epigenetics*. 2024 01 01;:429-473. <https://doi.org/10.1016/B978-0-443-23802-4.00009-0>
 40. Zhao S, Allis CD, Wang GC. The language of chromatin modification in human cancers. *Nature Reviews. Cancer*.

- 2021 07;21(7):413-430. <https://doi.org/10.1038/s41568-021-00357-x>
41. Hong CO, Choe MK, Roh T. Characterization of Chromatin Structure-associated Histone Modifications in Breast Cancer Cells. *Genomics & Informatics*. 2012 09;10(3):145-152. <https://doi.org/10.5808/GI.2012.10.3.145>
 42. Zhao Y, Chen Y, Jin M, Wang J. The crosstalk between m6A RNA methylation and other epigenetic regulators: a novel perspective in epigenetic remodeling. *Theranostics*. 2021;11(9):4549-4566. <https://doi.org/10.7150/thno.54967>
 43. Kinnerley B, Jung J, Cornish AJ, Chubb D, Laxton R, Frangou A, Gruber AJ, et al. Genomic landscape of diffuse glioma revealed by whole genome sequencing. *Nature Communications*. 2025 05 07;16(1):4233. <https://doi.org/10.1038/s41467-025-59156-9>
 44. Smith JC, Sheltzer JM. An integrated analysis of the epigenetic, genetic, and transcriptional patterns associated with outcome across cancer types. 2017 09 08;. <https://doi.org/10.1101/186528>
 45. Wang K, Yuen ST, Xu J, Lee SP, Yan HHN, Shi ST, Siu HC, et al. Whole-genome sequencing and comprehensive molecular profiling identify new driver mutations in gastric cancer. *Nature Genetics*. 2014 06;46(6):573-582. <https://doi.org/10.1038/ng.2983>
 46. Knijnenburg TA, Bismeyer T, Wessels LFA, Shmulevich I. A multilevel pan-cancer map links gene mutations to cancer hallmarks. *Chinese Journal of Cancer*. 2015 09 14;34(10):439-449. <https://doi.org/10.1186/s40880-015-0050-6>
 47. Boos L, Wicki A. The molecular tumor board—a key element of precision oncology. *memo - Magazine of European Medical Oncology*. 2024 09 01;17(3):190-193. <https://doi.org/10.1007/s12254-024-00977-7>
 48. Brognard J, Hunter T. Protein kinase signaling networks in cancer. *Current Opinion in Genetics & Development*. 2011 02;21(1):4-11. <https://doi.org/10.1016/j.gde.2010.10.012>
 49. Rubinfeld H, Seger R. The ERK cascade as a prototype of MAPK signaling pathways. *Methods in Molecular Biology*. 2004;250:1-28. <https://doi.org/10.1385/1-59259-671-1:1>
 50. Shapiro P. Ras-MAP kinase signaling pathways and control of cell proliferation: relevance to cancer therapy. *Critical Reviews in Clinical Laboratory Sciences*. 2002 09;39(4-5):285-330. <https://doi.org/10.1080/10408360290795538>
 51. Pearson GW, Earnest S, Cobb MH. Cyclic AMP selectively uncouples mitogen-activated protein kinase cascades from activating signals. *Molecular and Cellular Biology*. 2006 04;26(8):3039-3047. <https://doi.org/10.1128/MCB.26.8.3039-3047.2006>
 52. Petak I, Houghton JA, Kopper L. Molecular Targeting of Cell Death Signal Transduction Pathways in Cancer. *Current Signal Transduction Therapy*. 2006 01 01;1(1):113-131. <https://doi.org/10.2174/157436206775269217>
 53. Osford SME, Dallman CL, Johnson PWM, Ganesan A, Packham G. Current strategies to target the anti-apoptotic Bcl-2 protein in cancer cells. *Current Medicinal Chemistry*. 2004 04;11(8):1031-1039. <https://doi.org/10.2174/0929867043455486>
 54. Hervouet E, Cheray M, Vallette FM, Cartron P. DNA methylation and apoptosis resistance in cancer cells. *Cells*. 2013 07 18;2(3):545-573. <https://doi.org/10.3390/cells2030545>
 55. Chan ET, Kural C. Targeting endocytosis to sensitize cancer cells to programmed cell death. *Biochemical Society Transactions*. 2024 08 28;52(4):1703-1713. <https://doi.org/10.1042/BST20231332>
 56. Pentimalli F, Grelli S, Di Daniele N, Melino G, Amelio I. Cell death pathologies: targeting death pathways and the immune system for cancer therapy. *Genes and Immunity*. 2018 Dec 19;. <https://doi.org/10.1038/s41435-018-0052-x>
 57. Wilson TR, Johnston PG, Longley DB. Anti-apoptotic mechanisms of drug resistance in cancer. *Current Cancer Drug Targets*. 2009 05;9(3):307-319. <https://doi.org/10.2174/156800909788166547>
 58. Dosquet H, Neirinckx V, Meyrath M, Wantz M, Haan S, Niclou SP, Szpakowska M, Chevigné A. Nanoluciferase-based complementation assays to monitor activation, modulation and signaling of receptor tyrosine kinases (RTKs). *Methods in Enzymology*. 2023;682:1-16. <https://doi.org/10.1016/bs.mie.2022.09.002>
 59. Hubbard SR, Miller WT. Receptor tyrosine kinases: mechanisms of activation and signaling. *Current Opinion in Cell Biology*. 2007 04;19(2):117-123. <https://doi.org/10.1016/j.ceb.2007.02.010>
 60. Richman JM. Epidermal growth factor receptor family activation and intracellular signalling. Northeastern University [Dissertation]. <https://doi.org/10.17760/d10016788>
 61. Dengjel J, Kratchmarova I, Blagoev B. Receptor tyrosine kinase signaling: a view from quantitative proteomics. *Molecular bioSystems*. 2009 Oct;5(10):1112-1121. <https://doi.org/10.1039/b909534a>
 62. Butti R, Das S, Gunasekaran VP, Yadav AS, Kumar D, Kundu GC. Receptor tyrosine kinases (RTKs) in breast cancer: signaling, therapeutic implications and challenges. *Molecular Cancer*. 2018 02 19;17(1):34. <https://doi.org/10.1186/s12943-018-0797-x>
 63. Manzo LM, Lawaly M, Yu L. Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-small cell lung cancer. *Indian Journal of Pharmaceutical and Biological Research*. 2015 06 30;3(02):81-87. <https://doi.org/10.30750/ijpbr.3.2.10>
 64. Chen J, Zhu H, Yin Y, Jia S, Luo X. Colorectal cancer: Metabolic interactions reshape the tumor microenvironment. *Biochimica Et Biophysica Acta. Reviews on Cancer*. 2022 09;1877(5):188797. <https://doi.org/10.1016/j.bbcan.2022.188797>
 65. Sepúlveda F, Mayorga-Lobos C, Guzmán K, Durán-Jara E, Lobos-González. EV-miRNA-Mediated Intercellular Communication in the Breast Tumor Microenvironment. *International Journal of Molecular Sciences*. 2023 08 23;24(17):13085. <https://doi.org/10.3390/ijms241713085>
 66. Chen QY, Gao B, Tong D, Huang C. Crosstalk between extracellular vesicles and tumor-associated macrophage in the tumor microenvironment. *Cancer Letters*. 2023 01 01;552:215979. <https://doi.org/10.1016/j.canlet.2022.215979>
 67. Lou E, Subramanian S. Tunneling Nanotubes: Intercellular Conduits for Direct Cell-to-Cell Communication in Cancer. *Intercellular Communication in Cancer*. 2015;:201-225. https://doi.org/10.1007/978-94-017-7380-5_8
 68. Maffuid K, Cao Y. Decoding the Complexity of Immune-Cancer Cell Interactions: Empowering the Future of Cancer Immunotherapy. *Cancers*. 2023 08 21;15(16):4188. <https://doi.org/10.3390/cancers15164188>
 69. Swietlik JJ, Sinha A, Meissner F. Dissecting intercellular signaling with mass spectrometry-based proteomics. *Current Opinion in Cell Biology*. 2020 04;63:20-30. <https://doi.org/10.1016/j.ceb.2019.12.002>
 70. Xiong K, Fang Y, Qiu B, Chen C, Huang N, Liang F, Huang C, et al. Investigation of cellular communication and signaling pathways in tumor microenvironment for high TP53-expressing osteosarcoma cells through single-cell

- RNA sequencing. *Medical Oncology*. 2024 03 25;41(5):93. <https://doi.org/10.1007/s12032-024-02318-4>
71. Csermely P, Korcsmáros T, Nussinov R. Intracellular and intercellular signaling networks in cancer initiation, development and precision anti-cancer therapy: RAS acts as contextual signaling hub. *Seminars in Cell & Developmental Biology*. 2016 Oct;58:55-59. <https://doi.org/10.1016/j.semcdb.2016.07.005>
 72. Coschi CH, Juergens RA. Overcoming Resistance Mechanisms to Immune Checkpoint Inhibitors: Leveraging the Anti-Tumor Immune Response. *Current Oncology*. 2023 Dec 19;31(1):1-23. <https://doi.org/10.3390/curroncol31010001>
 73. Mortezaee K, Majidpoor J, Najafi S, Tasa D. Bypassing anti-PD-(L)1 therapy: Mechanisms and management strategies. *Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie*. 2023 02;158:114150. <https://doi.org/10.1016/j.biopha.2022.114150>
 74. Wang B, Han Y, Zhang Y, Zhao Q, Wang H, Wei J, Meng L, Xin Y, Jiang X. Overcoming acquired resistance to cancer immune checkpoint therapy: potential strategies based on molecular mechanisms. *Cell & Bioscience*. 2023 06 30;13(1):120. <https://doi.org/10.1186/s13578-023-01073-9>
 75. Qiu H, Shao Z, Wen X, Jiang J, Ma Q, Wang Y, Huang L, Ding X, Zhang L. TREM2: Keeping Pace With Immune Checkpoint Inhibitors in Cancer Immunotherapy. *Frontiers in Immunology*. 2021;12:716710. <https://doi.org/10.3389/fimmu.2021.716710>
 76. Jiang Y, Zhan H. Communication between EMT and PD-L1 signaling: New insights into tumor immune evasion. *Cancer Letters*. 2020 01 01;468:72-81. <https://doi.org/10.1016/j.canlet.2019.10.013>
 77. Jiang Z, Hsu JL, Li Y, Hortobagyi GN, Hung M. Cancer Cell Metabolism Bolsters Immunotherapy Resistance by Promoting an Immunosuppressive Tumor Microenvironment. *Frontiers in Oncology*. 2020;10:1197. <https://doi.org/10.3389/fonc.2020.01197>
 78. Ouyang P, Wang L, Wu J, Tian Y, Chen C, Li D, Yao Z, et al. Overcoming cold tumors: a combination strategy of immune checkpoint inhibitors. *Frontiers in Immunology*. 2024;15:1344272. <https://doi.org/10.3389/fimmu.2024.1344272>
 79. Turupati P, Usa D, India D, et al. Immune-microenvironment dynamics in cancer: Implications for immunotherapy. *Int J Adv Res*. 2024;12(05):903-7. <https://doi.org/10.21474/ijar01/18800>
 80. Yin Z, Song Y, Wang L. Single-cell RNA sequencing reveals the landscape of the cellular ecosystem of primary hepatocellular carcinoma. *Cancer Cell International*. 2024 Nov 14;24(1):379. <https://doi.org/10.1186/s12935-024-03574-0>
 81. Choudhary SG, Potdar PD. Review on Tumour Microenvironment Cell Types Associated with Metastatic Cancer. *Diseases & Research*. 2023 06 13;3(2):101-109. <https://doi.org/10.54457/DR.202302001>
 82. Ahuja S, Sureka N, Zaheer S. Unraveling the intricacies of cancer-associated fibroblasts: a comprehensive review on metabolic reprogramming and tumor microenvironment crosstalk. *APMIS: acta pathologica, microbiologica, et immunologica Scandinavica*. 2024 Dec;132(12):906-927. <https://doi.org/10.1111/apm.13447>
 83. Valiente-Alandi I, Schafer AE, Blaxall BC. Extracellular matrix-mediated cellular communication in the heart. *Journal of Molecular and Cellular Cardiology*. 2016 02;91:228-237. <https://doi.org/10.1016/j.yjmcc.2016.01.011>
 84. Bhat GR, Sethi I, Sadida HQ, Rah B, Mir R, Algehainy N, Albalawi IA, et al. Cancer cell plasticity: from cellular, molecular, and genetic mechanisms to tumor heterogeneity and drug resistance. *Cancer Metastasis Reviews*. 2024 03;43(1):197-228. <https://doi.org/10.1007/s10555-024-10172-z>
 85. Niland S, Riscanevo AX, Eble JA. Matrix Metalloproteinases Shape the Tumor Microenvironment in Cancer Progression. *International Journal of Molecular Sciences*. 2021 Dec 23;23(1):146. <https://doi.org/10.3390/ijms23010146>
 86. Noriega-Guerra H, Freitas VM. Extracellular Matrix Influencing HGF/c-MET Signaling Pathway: Impact on Cancer Progression. *International Journal of Molecular Sciences*. 2018 Oct 24;19(11):3300. <https://doi.org/10.3390/ijms19113300>
 87. Sato A, Rahman NIA, Shimizu A, Ogita H. Cell-to-cell contact-mediated regulation of tumor behavior in the tumor microenvironment. *Cancer Science*. 2021 Oct;112(10):4005-4012. <https://doi.org/10.1111/cas.15114>
 88. Miles FL, Sikes RA. Insidious changes in stromal matrix fuel cancer progression. *Molecular cancer research: MCR*. 2014 03;12(3):297-312. <https://doi.org/10.1158/1541-7786.MCR-13-0535>
 89. Mao X, Li Q, Gao Y, Zhou H, Liu Z, Jin W. Gap junction as an intercellular glue: Emerging roles in cancer EMT and metastasis. *Cancer Letters*. 2016 Oct 10;381(1):133-137. <https://doi.org/10.1016/j.canlet.2016.07.037>
 90. Antoon R, Overvest N, Saleh AH, Keating A. Mesenchymal stromal cells as cancer promoters. *Oncogene*. 2024 Nov;43(49):3545-3555. <https://doi.org/10.1038/s41388-024-03183-1>
 91. Biray Avci C, Goker Bagca B, Nikanfar M, Takanlou LS, Takanlou MS, Nourazarian A. Tumor microenvironment and cancer metastasis: molecular mechanisms and therapeutic implications. *Frontiers in Pharmacology*. 2024;15:1442888. <https://doi.org/10.3389/fphar.2024.1442888>
 92. Landskron G, De la Fuente M, Thuwajit P, Thuwajit C, Hermoso MA. Chronic inflammation and cytokines in the tumor microenvironment. *Journal of Immunology Research*. 2014;2014:149185. <https://doi.org/10.1155/2014/149185>
 93. Das D, Karthik N, Taneja R. Crosstalk Between Inflammatory Signaling and Methylation in Cancer. *Frontiers in Cell and Developmental Biology*. 2021;9:756458. <https://doi.org/10.3389/fcell.2021.756458>
 94. Xu K, Pedroza-Gonzalez A, Wu T, Asford C, Shafer S, Marches F, Gallegos M, et al. Promotion of breast cancer development via Th2 polarization by TSLP (165.2). *The Journal of Immunology*. 2011 04 01;186(1_Supplement):165.2. <https://doi.org/10.4049/jimmunol.186.Supp.165.2>
 95. Hirano T. IL-6 in inflammation, autoimmunity and cancer. *International Immunology*. 2021 03 01;33(3):127-148. <https://doi.org/10.1093/intimm/dxaa078>
 96. Chavez-Dominguez R, Perez-Medina M, Aguilar-Cazares D, Galicia-Velasco M, Meneses-Flores M, Islas-Vazquez L, Camarena A, Lopez-Gonzalez JS. Old and New Players of Inflammation and Their Relationship With Cancer Development. *Frontiers in Oncology*. 2021;11:722999. <https://doi.org/10.3389/fonc.2021.722999>
 97. Stephen NM, Deepika UR, Maradagi T, Sugawara T, Hirata T, Ganesan P. Insight on the cellular and molecular basis of blood vessel formation: A specific focus on tumor targets and therapy. *MedComm – Oncology*. 2023 03 01;2(1):n/a-n/a. <https://doi.org/10.1002/mog2.22>
 98. Yamada NO. Extracellular vesicles: emerging mediators of intercellular communication and tumor angiogenesis. *Annals of Translational Medicine*. 2017 02;5(3):59. <https://doi.org/10.1158/1744-4049.CCR.16.0101>

- doi.org/10.21037/atm.2017.01.14
99. Acker T, Plate KH. Role of hypoxia in tumor angiogenesis-molecular and cellular angiogenic crosstalk. *Cell and Tissue Research*. 2003 Oct;314(1):145-155. <https://doi.org/10.1007/s00441-003-0763-8>
 100. Wicki A, Christofori G. The Angiogenic Switch in Tumorigenesis. *Tumor Angiogenesis: Basic Mechanisms and Cancer Therapy*. 2008;;67-88. https://doi.org/10.1007/978-3-540-33177-3_4
 101. Rieger H, Welter M. Integrative models of vascular remodeling during tumor growth. *Wiley Interdisciplinary Reviews. Systems Biology and Medicine*. 2015 05;7(3):113-129. <https://doi.org/10.1002/wsbm.1295>
 102. Plein A, Fantin A, Ruhrberg C. Neuropilin regulation of angiogenesis, arteriogenesis, and vascular permeability. *Microcirculation*. 2014 05;21(4):315-323. <https://doi.org/10.1111/micc.12124>
 103. Kleinstreuer N, Dix D, Rountree M, Baker N, Sipes N, Reif D, Spencer R, Knudsen T. A computational model predicting disruption of blood vessel development. *PLoS computational biology*. 2013 04;9(4):e1002996. <https://doi.org/10.1371/journal.pcbi.1002996>
 104. Te Boekhorst V, Friedl P. Plasticity of Cancer Cell Invasion-Mechanisms and Implications for Therapy. *Advances in Cancer Research*. 2016;132:209-264. <https://doi.org/10.1016/bs.acr.2016.07.005>
 105. Fromme JE, Zigrino P. The Role of Extracellular Matrix Remodeling in Skin Tumor Progression and Therapeutic Resistance. *Frontiers in Molecular Biosciences*. 2022;9:864302. <https://doi.org/10.3389/fmolb.2022.864302>
 106. Meng J, Xu X, Jiang C, Xia P, Xu P, Tian L, Xu Y, et al. Tensile force field plays a crucial role in local invasion of tumor cells through a mechano-chemical coupling mechanism. *Soft Matter*. 2024 07 31;20(30):6002-6015. <https://doi.org/10.1039/d4sm00335g>
 107. Si H, Zhao N, Pedroza A, Rosen JM, Creighton CJ, Roarty K. Noncanonical Wnt/Ror2 signaling regulates cell-matrix crosstalk to prompt directional tumor cell invasion and dissemination in breast cancer. 2021 Dec 14;. <https://doi.org/10.1101/2021.05.15.444295>
 108. Thodeti CK, Ghosh K. Mechanisms of Tumor Cell Migration and Invasion in Lung Cancer Metastasis. *Lung Cancer Metastasis: Novel Biological Mechanisms and Impact on Clinical Practice*. 2010;;93-109. https://doi.org/10.1007/978-1-4419-0772-1_5
 109. Stetler-Stevenson WG, Liotta LA, Kleiner DE. Extracellular matrix 6: role of matrix metalloproteinases in tumor invasion and metastasis. *FASEB journal: official publication of the Federation of American Societies for Experimental Biology*. 1993 Dec;7(15):1434-1441. <https://doi.org/10.1096/fasebj.7.15.8262328>
 110. Goreczny GJ, Ouder Kirk-Pecone JL, Olson EC, Krendel M, Turner CE. Hic-5 remodeling of the stromal matrix promotes breast tumor progression. *Oncogene*. 2017 05 11;36(19):2693-2703. <https://doi.org/10.1038/onc.2016.422>
 111. Toehawng L, Deng S, Pervaiz S, Yap CT. Redox regulation of cancer cell migration and invasion. *Mitochondrion*. 2013 05;13(3):246-253. <https://doi.org/10.1016/j.mito.2012.08.002>
 112. Wu J, Jiang J, Chen B, Wang K, Tang Y, Liang X. Plasticity of cancer cell invasion: Patterns and mechanisms. *Translational Oncology*. 2021 01;14(1):100899. <https://doi.org/10.1016/j.tranon.2020.100899>
 113. Friedl P, Wolf K. Tumour-cell invasion and migration: diversity and escape mechanisms. *Nature Reviews. Cancer*. 2003 05;3(5):362-374. <https://doi.org/10.1038/nrc1075>
 114. Wu J, Sheng S, Liang X, Tang Y. The role of tumor microenvironment in collective tumor cell invasion. *Future Oncology*. 2017 05;13(11):991-1002. <https://doi.org/10.2217/fon-2016-0501>
 115. Brabletz T, Kalluri R, Nieto MA, Weinberg RA. EMT in cancer. *Nature Reviews. Cancer*. 2018 02;18(2):128-134. <https://doi.org/10.1038/nrc.2017.118>
 116. Kalluri R, Weinberg RA. The basics of epithelial-mesenchymal transition. *The Journal of Clinical Investigation*. 2009 06;119(6):1420-1428. <https://doi.org/10.1172/JCI39104>
 117. Khan SU, Fatima K, Malik F, Kalkavan H, Wani A. Cancer metastasis: Molecular mechanisms and clinical perspectives. *Pharmacology & Therapeutics*. 2023 Oct;250:108522. <https://doi.org/10.1016/j.pharmthera.2023.108522>
 118. Pantel K, Alix-Panabières C. Crucial roles of circulating tumor cells in the metastatic cascade and tumor immune escape: biology and clinical translation. *Journal for Immunotherapy of Cancer*. 2022 Dec;10(12):e005615. <https://doi.org/10.1136/jitc-2022-005615>
 119. Haynes NM, Chadwick TB, Parker BS. The complexity of immune evasion mechanisms throughout the metastatic cascade. *Nature Immunology*. 2024 Oct;25(10):1793-1808. <https://doi.org/10.1038/s41590-024-01960-4>
 120. Lee JJ, Ven RAH, Zaganjor E, Ng MR, Barakat A, Demmers JJP, Finley LWS, et al. Inhibition of epithelial cell migration and Src/FAK signaling by SIRT3. *Proceedings of the National Academy of Sciences of the United States of America*. 2018 07 03;115(27):7057-7062. <https://doi.org/10.1073/pnas.1800440115>
 121. Wang W, Kansakar U, Markovic V, Sossey-Alaoui K. Role of Kindlin-2 in cancer progression and metastasis. *Annals of Translational Medicine*. 2020 07;8(14):901. <https://doi.org/10.21037/atm.2020.03.64>
 122. Du Y, You L, Ren X, Liu Z, Zhao Y. Roles of NF-κB signaling pathway in regulatory network of pancreatic cancer metastasis. *International Journal of Surgery*. 2014;;622-625.
 123. Minn AJ, Bevilacqua E, Yun J, Rosner MR. Identification of novel metastasis suppressor signaling pathways for breast cancer. *Cell Cycle*. 2012 07 01;11(13):2452-2457. <https://doi.org/10.4161/cc.20624>
 124. Dai Y, Shi W, Molnar N, Siemann D. Impact of Tumor Hypoxia, Src, and Met Signaling in the Dissemination of Tumor Cells. 2011;;171-194. https://doi.org/10.1007/978-94-007-2558-4_7
 125. Maishi N, Hida K. Tumor endothelial cells accelerate tumor metastasis. *Cancer Science*. 2017 Oct;108(10):1921-1926. <https://doi.org/10.1111/cas.13336>
 126. Radinsky R, Bucana CD, Cho CH. Molecular Mechanisms of Tumor Cell Survival, Growth, and Apoptosis During Organ-Specific Metastasis. *Microscopy and Microanalysis*. 1997;3(S2):33-34.
 127. Piaseczny MM, Pio GM, Chu JE, Xia Y, Nguyen K, Goodale D, Allan A. Generation of Organ-conditioned Media and Applications for Studying Organ-specific Influences on Breast Cancer Metastatic Behavior. *Journal of Visualized Experiments: JoVE*. 2016 06 13;(112):54037. <https://doi.org/10.3791/54037>
 128. Radinsky R. Paracrine growth regulation of human colon carcinoma organ-specific metastasis. *Cancer Metastasis Reviews*. 1993 09;12(3-4):345-361. <https://doi.org/10.1007/BF00665962>
 129. Liu Z, Chen J, Ren Y, Liu S, Ba Y, Zuo A, Luo P, et al. Multi-stage mechanisms of tumor metastasis and therapeutic strategies. *Signal Transduction and Targeted Therapy*. 2024 Oct 11;9(1):270. <https://doi.org/10.1038/s41392-024->

- 01955-5
130. Dafflon C, Santamaría-Martínez A, Ordóñez-Morán P. An Intraspinal Injection Model for the Study of Cancer Stem Cell Seeding Capacity. *Methods in Molecular Biology*. 2020;2171:293-302. https://doi.org/10.1007/978-1-0716-0747-3_20
 131. Shibue T, Weinberg RA. Metastatic colonization: settlement, adaptation and propagation of tumor cells in a foreign tissue environment. *Seminars in Cancer Biology*. 2011 04;21(2):99-106. <https://doi.org/10.1016/j.semcancer.2010.12.003>
 132. Wang Z, Wu X, Chen H, Wang K. Amino acid metabolic reprogramming in tumor metastatic colonization. *Frontiers in Oncology*. 2023;13:1123192. <https://doi.org/10.3389/fonc.2023.1123192>
 133. Liu Y, Mao D, Wang H, Che X, Chen Y. Formation of pre-metastatic niches induced by tumor extracellular vesicles in lung metastasis. *Pharmacological Research*. 2023 02;188:106669. <https://doi.org/10.1016/j.phrs.2023.106669>
 134. Melone MAB, Valentino A, Margarucci S, Galderisi U, Giordano A, Peluso G. The carnitine system and cancer metabolic plasticity. *Cell Death & Disease*. 2018 02 14;9(2):228. <https://doi.org/10.1038/s41419-018-0313-7>
 135. Ruggieri F, Jonas K, Ferracin M, Dengler M, Jäger V, Pichler M. MicroRNAs as regulators of tumor metabolism. *Endocrine-Related Cancer*. 2023 08 01;30(8):e220267. <https://doi.org/10.1530/ERC-22-0267>
 136. Vanhove K, Graulus G, Mesotten L, Thomeer M, Derveaux E, Noben J, Guedens W, Adriaensens P. The Metabolic Landscape of Lung Cancer: New Insights in a Disturbed Glucose Metabolism. *Frontiers in Oncology*. 2019;9:1215. <https://doi.org/10.3389/fonc.2019.01215>
 137. Suriya Muthukumar N, Velusamy P, Akino Mercy CS, Langford D, Natarajaseenivasan K, Shanmughapriya S. MicroRNAs as Regulators of Cancer Cell Energy Metabolism. *Journal of Personalized Medicine*. 2022 08 18;12(8):1329. <https://doi.org/10.3390/jpm12081329>
 138. Li X, Liu M, Liu H, Chen J. Tumor metabolic reprogramming in lung cancer progression. *Oncology Letters*. 2022 08;24(2):287. <https://doi.org/10.3892/ol.2022.13407>
 139. Rana PS, Goparaju K, Driscoll JJ. Shutting off the fuel supply to target metabolic vulnerabilities in multiple myeloma. *Frontiers in Oncology*. 2023;13:1141851. <https://doi.org/10.3389/fonc.2023.1141851>
 140. Ali JS, Ain NU, Naz S, Zia M. Biomarker selection and imaging design in cancer: A link with biochemical pathways for imminent engineering. *Heliyon*. 2020 02;6(2):e03340. <https://doi.org/10.1016/j.heliyon.2020.e03340>
 141. Adapa SR, Hunter GA, Amin NE, Marinescu C, Borsky A, Sagatys EM, Sebti SM, et al. Porphyrin overdrive rewires pan-cancer cell metabolism. 2023 Oct 26;. <https://doi.org/10.1101/2022.02.18.481061>
 142. Kooshan Z, Srinivasan S, Janjua TI, Popat A, Batra J. Lactoferrin conjugated radicol nanparticles enhanced drug delivery and cytotoxicity in prostate cancer cells. *European Journal of Pharmacology*. 2025 03 15;991:177300. <https://doi.org/10.1016/j.ejphar.2025.177300>
 143. Proal AD, VanElzakker MB. Pathogens Hijack Host Cell Metabolism: Intracellular Infection as a Driver of the Warburg Effect in Cancer and Other Chronic Inflammatory Conditions. *Immunometabolism*. 2021 01;3(1):e210003. <https://doi.org/10.20900/immunometab20210003>
 144. Kozal K, Józwiak P, Krześlak A. Contemporary Perspectives on the Warburg Effect Inhibition in Cancer Therapy. *Cancer Control: Journal of the Moffitt Cancer Center*. 2021;28:10732748211041243. <https://doi.org/10.1177/10732748211041243>
 145. Agnihotri S, Zadeh G. Metabolic reprogramming in glioblastoma: the influence of cancer metabolism on epigenetics and unanswered questions. *Neuro-Oncology*. 2016 02;18(2):160-172. <https://doi.org/10.1093/neuonc/nov125>
 146. Lee M. Metabolic interplay between glycolysis and mitochondrial oxidation: The reverse Warburg effect and its therapeutic implication. *World Journal of Biological Chemistry*. 2015;6(3):148. <https://doi.org/10.4331/wjbc.v6.i3.148>
 147. Bai R, Meng Y, Cui J. Therapeutic strategies targeting metabolic characteristics of cancer cells. *Critical Reviews in Oncology/Hematology*. 2023 07;187:104037. <https://doi.org/10.1016/j.critrevonc.2023.104037>
 148. Tarrado-Castellarnau M, Atauri P, Cascante M. Oncogenic regulation of tumor metabolic reprogramming. *Oncotarget*. 2016 09 20;7(38):62726-62753. <https://doi.org/10.18632/oncotarget.10911>
 149. Bajpai R, Shanmugam M. Targeting cancer metabolism through synthetic lethality-based combinatorial treatment strategies. *Current Opinion in Oncology*. 2018 09;30(5):338-344. <https://doi.org/10.1097/CCO.0000000000000467>
 150. El-Tanani M, Rabbani SA, El-Tanani Y, Matalka II. Metabolic vulnerabilities in cancer: A new therapeutic strategy. *Critical Reviews in Oncology/Hematology*. 2024 09;201:104438. <https://doi.org/10.1016/j.critrevonc.2024.104438>
 151. Kalyanaraman B, Cheng G, Hardy M. Therapeutic Targeting of Tumor Cells and Tumor Immune Microenvironment Vulnerabilities. *Frontiers in Oncology*. 2022;12:816504. <https://doi.org/10.3389/fonc.2022.816504>
 152. Zhao B, Wang J, Chen L, Wang H, Liang C, Huang J, Xu L. The role of glutamine metabolism in castration-resistant prostate cancer. *Asian Journal of Andrology*. 2023;25(2):192-197. <https://doi.org/10.4103/aja2022105>
 153. Tripathi SC, Fahrman JF, Vykoukal JV, Dennison JB, Hanash SM. Targeting metabolic vulnerabilities of cancer: Small molecule inhibitors in clinic. *Cancer Reports*. 2019 02;2(1):e1131. <https://doi.org/10.1002/cnr2.1131>
 154. Hyrošová P, Milošević M, Škoda J, Vachtenheim J, Rohlena J, Rohlenová K. Effects of metabolic cancer therapy on tumor microenvironment. *Frontiers in Oncology*. 2022;12:1046630. <https://doi.org/10.3389/fonc.2022.1046630>
 155. Li J, Eu JQ, Kong LR, Wang L, Lim YC, Goh BC, Wong ALA. Targeting Metabolism in Cancer Cells and the Tumour Microenvironment for Cancer Therapy. *Molecules*. 2020 Oct 20;25(20):4831. <https://doi.org/10.3390/molecules25204831>
 156. Wegiel B, Vuerich M, Daneshmandi S, Seth P. Metabolic Switch in the Tumor Microenvironment Determines Immune Responses to Anti-cancer Therapy. *Frontiers in Oncology*. 2018;8:284. <https://doi.org/10.3389/fonc.2018.00284>
 157. Zhang X, Ma H, Gao Y, Liang Y, Du Y, Hao S, Ni T. The Tumor Microenvironment: Signal Transduction. *Biomolecules*. 2024 04 04;14(4):438. <https://doi.org/10.3390/biom14040438>
 158. Dias AS, Almeida CR, Helguero LA, Duarte IF. Metabolic crosstalk in the breast cancer microenvironment. *European Journal of Cancer*. 2019 Nov;121:154-171. <https://doi.org/10.1016/j.ejca.2019.09.002>
 159. Corn KC, Windham MA, Rafat M. Lipids in the tumor microenvironment: From cancer progression to treatment. *Progress in Lipid Research*. 2020 Nov;80:101055. <https://doi.org/10.1016/j.plipres.2020.101055>
 160. Zhu Y, Li X, Wang L, Hong X, Yang J. Metabolic reprogramming and crosstalk of cancer-related fibroblasts and immune cells in the tumor microenvironment. *Frontiers in Endocrinology*. 2022;13:988295. <https://doi.org/10.3389/>

- fendo.2022.988295
161. Asha BB. Advances in Targeted Therapy for Cancer: Precision Medicine Approaches. *IDOSR J Appl Sci.* 2024;9(2):63-7. <https://doi.org/10.59298/idosrjas/2024/9.2.636700>
 162. Stoffel A. Targeted therapies for solid tumors: current status and future perspectives. *BioDrugs: Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy.* 2010 Oct 01;24(5):303-316. <https://doi.org/10.2165/11535880-000000000-00000>
 163. Sabaawy HE. Genetic Heterogeneity and Clonal Evolution of Tumor Cells and their Impact on Precision Cancer Medicine. *Journal of Leukemia.* 2013 Nov 18;1(4):1000124. <https://doi.org/10.4172/2329-6917.1000124>
 164. Noor ZS., Cummings AL, Spiegel ML, et al. Targeted Therapy for Non-Small Cell Lung Cancer. *Semin Respir Crit Care Med.* 2020;41(3):409-34. <https://doi.org/10.1055/s-0039-1700994>
 165. Planchard D. Identification of driver mutations in lung cancer: first step in personalized cancer. *Targeted Oncology.* 2013 03;8(1):3-14. <https://doi.org/10.1007/s11523-013-0263-z>
 166. Pectasides E. Genomic Alterations and Targeted Therapy in Gastric and Esophageal Adenocarcinoma. *Clinical Therapeutics.* 2016 07;38(7):1589-1599. <https://doi.org/10.1016/j.clinthera.2016.03.016>
 167. Bhambre AS, Giri AB, Mundhe SA, Mahadik AB, Bhambre AS, Giri AB, Mundhe SA, Mahadik AB. Precision and personalized medicine: new way for cancer management. *GSC Biological and Pharmaceutical Sciences.* 2022;18(3):046-053. <https://doi.org/10.30574/gscbps.2022.18.3.0042>
 168. Gadade DD, Jha H, Kumar C, Khan F. Unlocking the power of precision medicine: exploring the role of biomarkers in cancer management. *Future Journal of Pharmaceutical Sciences.* 2024 01 05;10(1):5. <https://doi.org/10.1186/s43094-023-00573-2>
 169. Pauli C, Puca L, Hopkins B, Emerling BM, Sboner A, Elemento O, McNary TJ, et al. Abstract A20: Personalized models to guide precision medicine. *Clinical Cancer Research.* 2016 08 15;22(16_Supplement):A20. <https://doi.org/10.1158/1557-3265.PDX16-A20>
 170. Matchett KB, Lynam-Lennon N, Brown JAL, Watson RW. Advancing Precision Medicine: Tailoring Personalized Therapies. *Jenny Stanford.* 2019;:393-410. <https://doi.org/10.1201/9780429295010-10>
 171. Sekeroglu ZA, Sekeroglu V. A Review on Patient-derived 3D Micro Cancer Approach for Drug Screen in Personalized Cancer Medicine. *Current Cancer Drug Targets.* 2025;25(2):118-130. <https://doi.org/10.2174/0115680096285910240206044830>
 172. Mulvey CK. Emerging Precision Medicine Approaches for Lung Neuroendocrine Tumors. *Cancers.* 2023 Nov 25;15(23):5575. <https://doi.org/10.3390/cancers15235575>
 173. Garg P, Malhotra J, Kulkarni P, Horne D, Salgia R, Singhal SS. Emerging Therapeutic Strategies to Overcome Drug Resistance in Cancer Cells. *Cancers.* 2024 07 07;16(13):2478. <https://doi.org/10.3390/cancers16132478>
 174. Jia J, Wu X, Long G, Yu J, He W, Zhang H, Wang D, Ye Z, Tian J. Revolutionizing cancer treatment: nanotechnology-enabled photodynamic therapy and immunotherapy with advanced photosensitizers. *Frontiers in Immunology.* 2023;14:1219785. <https://doi.org/10.3389/fimmu.2023.1219785>
 175. Yu X, Xu C, Sun J, Xu H, Huang H, Gan Z, George A, Ouyang S, Liu F. Recent developments in two-dimensional molybdenum disulfide-based multimodal cancer theranostics. *Journal of Nanobiotechnology.* 2024 08 28;22(1):515. <https://doi.org/10.1186/s12951-024-02785-x>
 176. Tez M, Sahingöz E, Martlı F. Molecular underpinnings of pancreatic cancer: Innovations in treatment and future perspectives. *Gastrointestinal Tract.* 2023 05 25;1. <https://doi.org/10.54844/git.2023.496>
 177. Mabonga L, Fourie L, Kappo AP, et al. Chapter Six - Emerging treatment approaches for colorectal cancer treatment resistance. In: *Colorectal Cancer Treatment Resistance.* Elsevier. 2025 01 01;:107-145. <https://doi.org/10.1016/B978-0-443-33475-7.00001-9>
 178. La'ah AS, Chiou S. Cutting-Edge Therapies for Lung Cancer. *Cells.* 2024 03 01;13(5):436. <https://doi.org/10.3390/cells13050436>
 179. Benedetto G, Vestal CG, Richardson C. Aptamer-Functionalized Nanoparticles as “Smart Bombs”: The Unrealized Potential for Personalized Medicine and Targeted Cancer Treatment. *Targeted Oncology.* 2015 Dec;10(4):467-485. <https://doi.org/10.1007/s11523-015-0371-z>
 180. Tilak TVSVGK, Patel A, Kapoor A. Molecular basis and clinical application of targeted therapy in oncology. *Medical Journal, Armed Forces India.* 2023;79(2):128-135. <https://doi.org/10.1016/j.mjafi.2023.02.001>
 181. Balik K, Bajek A, Modrakowska P, Maj M, Kaźmierski Ł. Limitations of molecularly targeted therapy. *Med Res J.* 2019;4(2):99-105. <https://doi.org/10.5603/mrj.a2019.0016>



This work is licensed under a Creative Commons Attribution-Non Commercial 4.0 International License.